Paul Mahon Biography and Net Worth

Mr. Mahon has served as General Counsel and Corporate Secretary of United Therapeutics since its inception in 1996. In 2001, Mr. Mahon joined United Therapeutics full-time as Senior Vice President, General Counsel and Corporate Secretary. In 2003, Mr. Mahon was promoted to Executive Vice President, General Counsel and Corporate Secretary. Prior to 2001, he served United Therapeutics, beginning with its formation in 1996, in his capacity as principal and managing partner of a law firm specializing in technology and media law.

What is Paul A. Mahon's net worth?: The estimated net worth of Paul A. Mahon is at least $11.31 million as of December 5th, 2024. Mr. Mahon owns 36,710 shares of United Therapeutics stock worth more than $11,307,414 as of March 28th. This net worth approximation does not reflect any other assets that Mr. Mahon may own. Additionally, Mr. Mahon receives a salary of $2,440,000.00 as EVP at United Therapeutics. Learn More about Paul A. Mahon's net worth.
How old is Paul A. Mahon?: Mr. Mahon is currently 60 years old. There are 4 older executives and no younger executives at United Therapeutics. The oldest executive at United Therapeutics is Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D., Founder, Chairman & CEO, who is 69 years old. Learn More on Paul A. Mahon's age.
What is Paul A. Mahon's salary?: As the EVP of United Therapeutics Co., Mr. Mahon earns $2,440,000.00 per year. There are 2 executives that earn more than Mr. Mahon. The highest earning executive at United Therapeutics is Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D., Founder, Chairman & CEO, who commands a salary of $5,660,000.00 per year. Learn More on Paul A. Mahon's salary.
How do I contact Paul A. Mahon?: The corporate mailing address for Mr. Mahon and other United Therapeutics executives is 1040 SPRING ST, SILVER SPRING MD, 20910. United Therapeutics can also be reached via phone at (301) 608-9292 and via email at ir@unither.com. Learn More on Paul A. Mahon's contact information.
Has Paul A. Mahon been buying or selling shares of United Therapeutics?: Paul A. Mahon has not been actively trading shares of United Therapeutics during the last quarter. Most recently, Paul A. Mahon sold 7,700 shares of the business's stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $374.37, for a transaction totalling $2,882,649.00. Following the completion of the sale, the executive vice president now directly owns 36,710 shares of the company's stock, valued at $13,743,122.70. Learn More on Paul A. Mahon's trading history.
Who are United Therapeutics' active insiders?: United Therapeutics' insider roster includes Michael Benkowitz (COO), Christopher Causey (Director), Raymond Dwek (Director), James Edgemond (CFO), Paul Mahon (EVP), Nilda Mesa (Director), Judy Olian (Director), Christopher Patusky (Director), Martine Rothblatt (CEO), Louis Sullivan (Director), and Tommy Thompson (Director). Learn More on United Therapeutics' active insiders.
Are insiders buying or selling shares of United Therapeutics?: During the last twelve months, insiders at the biotechnology company sold shares 80 times. They sold a total of 482,229 shares worth more than $157,900,610.37. The most recent insider tranaction occured on March, 24th when Director Tommy G Thompson sold 2,500 shares worth more than $797,000.00. Insiders at United Therapeutics own 11.9% of the company. Learn More about insider trades at United Therapeutics.
Information on this page was last updated on 3/24/2025.

Paul A. Mahon Insider Trading History at United Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/5/2024	Sell	7,700	$374.37	$2,882,649.00	36,710
11/21/2024	Sell	7,700	$367.36	$2,828,672.00	36,710
4/4/2024	Sell	6,000	$232.37	$1,394,220.00	36,710
3/21/2024	Sell	6,000	$236.45	$1,418,700.00	36,710
2/15/2024	Sell	6,000	$215.31	$1,291,860.00	36,599
2/1/2024	Sell	6,000	$215.01	$1,290,060.00	36,599
1/18/2024	Sell	6,000	$218.72	$1,312,320.00	36,599
1/4/2024	Sell	6,000	$227.97	$1,367,820.00	36,599
12/21/2023	Sell	6,000	$229.27	$1,375,620.00	36,599
12/7/2023	Sell	6,000	$238.89	$1,433,340.00	36,599
11/2/2023	Sell	6,000	$225.76	$1,354,560.00	36,599
10/19/2023	Sell	6,000	$225.43	$1,352,580.00	36,599
10/5/2023	Sell	6,000	$223.82	$1,342,920.00	36,599
9/21/2023	Sell	6,000	$222.19	$1,333,140.00	36,599
9/7/2023	Sell	6,000	$222.98	$1,337,880.00	36,599
8/3/2023	Sell	6,000	$236.25	$1,417,500.00	36,599
7/20/2023	Sell	2,500	$243.87	$609,675.00	36,599
7/6/2023	Sell	6,000	$215.19	$1,291,140.00	36,599
6/15/2023	Sell	6,000	$227.77	$1,366,620.00	36,599
6/1/2023	Sell	6,000	$209.11	$1,254,660.00	36,599
5/18/2023	Sell	6,000	$214.58	$1,287,480.00	36,599
5/4/2023	Sell	6,000	$215.82	$1,294,920.00	36,599
4/20/2023	Sell	6,000	$223.96	$1,343,760.00	36,599
4/6/2023	Sell	6,000	$232.79	$1,396,740.00	36,599
3/16/2023	Sell	6,000	$214.39	$1,286,340.00	36,599
2/2/2023	Sell	6,000	$254.63	$1,527,780.00	36,397
1/19/2023	Sell	6,000	$258.95	$1,553,700.00	36,397
12/15/2022	Sell	12,000	$196.31	$2,355,720.00	36,397
12/1/2022	Sell	6,000	$277.65	$1,665,900.00	36,397
11/3/2022	Sell	6,000	$257.08	$1,542,480.00	36,397
10/20/2022	Sell	6,000	$216.68	$1,300,080.00	36,397
10/6/2022	Sell	6,000	$209.26	$1,255,560.00	36,397
9/22/2022	Sell	6,000	$203.34	$1,220,040.00	36,397
8/4/2022	Sell	4,552	$225.81	$1,027,887.12	36,397
7/21/2022	Sell	6,000	$226.27	$1,357,620.00	36,397
7/7/2022	Sell	6,000	$242.04	$1,452,240.00	36,397
6/16/2022	Sell	6,000	$215.58	$1,293,480.00	36,397
5/19/2022	Sell	6,000	$183.43	$1,100,580.00	36,397
5/5/2022	Sell	6,000	$190.65	$1,143,900.00	36,397
4/21/2022	Sell	6,000	$189.18	$1,135,080.00	36,397
4/7/2022	Sell	6,000	$185.52	$1,113,120.00	36,487
3/17/2022	Sell	6,000	$182.42	$1,094,520.00
3/3/2022	Sell	6,000	$174.12	$1,044,720.00
2/17/2022	Sell	6,000	$202.17	$1,213,020.00
2/3/2022	Sell	6,000	$200.10	$1,200,600.00
1/20/2022	Sell	6,000	$205.57	$1,233,420.00
1/6/2022	Sell	6,000	$192.46	$1,154,760.00
12/16/2021	Sell	6,000	$195.53	$1,173,180.00
12/2/2021	Sell	6,000	$189.36	$1,136,160.00
11/4/2021	Sell	6,000	$201.19	$1,207,140.00
10/21/2021	Sell	6,000	$190.18	$1,141,080.00
10/7/2021	Sell	6,000	$190.52	$1,143,120.00
9/16/2021	Sell	6,000	$204.08	$1,224,480.00	42,369
9/2/2021	Sell	6,000	$210.94	$1,265,640.00	42,369
10/1/2015	Sell	6,000	$129.38	$776,280.00	35,054
4/16/2015	Sell	6,000	$187.91	$1,127,460.00
4/2/2015	Sell	6,000	$174.73	$1,048,380.00
3/19/2015	Sell	6,000	$175.82	$1,054,920.00
2/19/2015	Sell	6,000	$155.72	$934,320.00
2/5/2015	Sell	6,000	$141.92	$851,520.00
1/15/2015	Sell	6,000	$137.84	$827,040.00
1/2/2015	Sell	6,000	$127.73	$766,380.00
12/18/2014	Sell	10,750	$130.03	$1,397,822.50
12/4/2014	Sell	11,000	$129.92	$1,429,120.00
11/20/2014	Sell	11,000	$129.02	$1,419,220.00
11/6/2014	Sell	5,000	$125.02	$625,100.00
10/23/2014	Sell	11,000	$127.04	$1,397,440.00
10/9/2014	Sell	5,000	$130.59	$652,950.00
10/2/2014	Sell	6,000	$129.46	$776,760.00
9/25/2014	Sell	5,000	$133.77	$668,850.00
9/18/2014	Sell	6,000	$130.93	$785,580.00
9/11/2014	Sell	5,000	$120.70	$603,500.00
9/4/2014	Sell	6,000	$112.38	$674,280.00
8/28/2014	Sell	5,000	$92.07	$460,350.00
8/14/2014	Sell	10,000	$88.41	$884,100.00
6/19/2014	Sell	2,000	$85.67	$171,340.00
6/5/2014	Sell	6,000	$96.50	$579,000.00
10/17/2013	Sell	6,000	$81.79	$490,740.00
10/3/2013	Sell	6,000	$84.38	$506,280.00
9/5/2013	Sell	6,000	$73.29	$439,740.00
8/1/2013	Sell	6,000	$75.91	$455,460.00
7/18/2013	Sell	6,000	$69.15	$414,900.00
7/5/2013	Sell	6,000	$67.04	$402,240.00
6/20/2013	Sell	6,000	$63.29	$379,740.00
6/6/2013	Sell	6,000	$63.84	$383,040.00
5/16/2013	Sell	6,000	$68.05	$408,300.00
5/2/2013	Sell	6,000	$67.15	$402,900.00
1/17/2013	Sell	5,749	$52.20	$300,097.80
10/4/2012	Sell	6,000	$38.00	$228,000.00

See Full Table

Paul A. Mahon Buying and Selling Activity at United Therapeutics

United Therapeutics Company Overview

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Today's Range

Now: $308.02

$307.57

$318.40

50 Day Range

MA: $341.10

$304.42

$380.78

2 Week Range

Now: $308.02

$221.53

$417.82

Volume

302,824 shs

Average Volume

442,403 shs

Market Capitalization

$13.83 billion

P/E Ratio

13.53

Dividend Yield

N/A

Beta

0.64

Paul Mahon Biography and Net Worth

What is Paul A. Mahon's net worth?

How old is Paul A. Mahon?

What is Paul A. Mahon's salary?

How do I contact Paul A. Mahon?

Has Paul A. Mahon been buying or selling shares of United Therapeutics?

Who are United Therapeutics' active insiders?

Are insiders buying or selling shares of United Therapeutics?